Drugs / RBMRNA-405
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05897190 | May → Jun 2022 | Orthocoronavirinae infectious disease | Argorna Pharmaceuticals Co., LTD | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RBMRNA-405 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05897190 ↗ |
| Modality | Messenger RNA (mRNA) | “the bivalent COVID-19 mRNA vaccine RBMRNA-405” PMID 41882056 ↗ Mar 2026 |